Annual Drug Patent Expirations for PLENVU
Plenvu is a drug marketed by Salix and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for PLENVU.
This drug has one hundred and twenty-nine patent family members in thirty-six countries.
The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. One supplier is listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
